ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05059444 |
Recruitment Status :
Recruiting
First Posted : September 28, 2021
Last Update Posted : September 9, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Bladder Carcinoma Ureter Carcinoma Renal Pelvis Carcinoma Non-small Cell Lung Cancer Invasive Breast Carcinoma Cutaneous Melanoma Esophageal Carcinoma Gastroesophageal Junction Carcinoma Gastric Adenocarcinoma Pancreatic Adenocarcinoma Squamous Cell Carcinoma of the Head and Neck Epithelial Ovarian Carcinoma Fallopian Tube Carcinoma Endometrial Carcinoma Renal Cell Carcinoma | Diagnostic Test: Guardant Reveal |
Study Type : | Observational |
Estimated Enrollment : | 1000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation |
Actual Study Start Date : | September 7, 2021 |
Estimated Primary Completion Date : | February 2028 |
Estimated Study Completion Date : | February 2028 |
Group/Cohort | Intervention/treatment |
---|---|
Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III) |
Diagnostic Test: Guardant Reveal
Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors. |
Cohort 2: Non-small cell lung cancer (stage II-III) |
Diagnostic Test: Guardant Reveal
Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors. |
Cohort 3: Invasive breast carcinoma with all of the following:
|
Diagnostic Test: Guardant Reveal
Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors. |
Cohort 4: Stage IIb-III cutaneous melanoma or limited (resectable) stage IV melanoma |
Diagnostic Test: Guardant Reveal
Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors. |
Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III) |
Diagnostic Test: Guardant Reveal
Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors. |
Cohort 6: Gastric adenocarcinoma (stage II-III) |
Diagnostic Test: Guardant Reveal
Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors. |
Cohort 7: Surgically resected pancreatic adenocarcinoma |
Diagnostic Test: Guardant Reveal
Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors. |
Cohort 8: Invasive squamous cell carcinoma of the head and neck
Includes stage I-III oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, paranasal sinus, and salivary gland cancers.
|
Diagnostic Test: Guardant Reveal
Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors. |
Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma
Defined as stage IC-III or stage I that has high grade (grade 3-4) or clear cell histology).
|
Diagnostic Test: Guardant Reveal
Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors. |
Cohort 10: High-risk endometrial carcinoma
Defined as having any of the following: serous or clear cell adenocarcinoma histology (any stage), grade 3 or 4 deeply invasive (T1b or greater) endometrioid carcinoma, stage III disease (any histology).
|
Diagnostic Test: Guardant Reveal
Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors. |
Cohort 11: High-risk renal cell carcinoma
Defined as high grade (grade 3-4) stage II, stage III or limited (resectable) stage IV treated with curative intent.
|
Diagnostic Test: Guardant Reveal
Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors. |
- Distant Recurrence Free Interval (D-RFi) [ Time Frame: 6 years ]The primary endpoint, distant recurrence-free interval (D-RFi), will be evaluated for each of the primary study cohorts. D-RFi is defined as the time from the end of primary treatment until the time of diagnosis of a distant recurrence of the Index Cancer. Subjects without a distant recurrence will be censored at the time of last follow-up of their Index Cancer.
- Sensitivity [ Time Frame: 6 years ]Sensitivity defined as the proportion of participants who develop distant recurrence who have ctDNA detected at or before the time of clinical detection of recurrence.
- Positive Predictive Value [ Time Frame: 6 years ]Positive predictive value (PPV) defined as the proportion of participants who have ctDNA detected at the landmark or any surveillance timepoint who recur (either distally or locally).
- Lead Time [ Time Frame: 6 years ]Lead time defined as the interval between ctDNA detection and clinical detection of recurrence.
- Recurrence-free interval (RFi) [ Time Frame: 6 years ]Recurrence-free interval (RFi) defined as the time from the end of primary treatment until the appearance/occurrence of any recurrence (distant, regional, and/or local) of the Index Cancer. Subjects without recurrence will be censored at the time of last follow-up of their Index Cancer.
- Negative predictive value (NPV) [ Time Frame: 6 years ]Negative predictive value (NPV) defined as the proportion of participants who have ctDNA not detected who have no evidence of recurrence.
- Association with resolution of indeterminate findings [ Time Frame: 6 years ]
- The proportion of individuals whose indeterminate finding is ultimately confirmed to be disease recurrence who have ctDNA detected at the initial time the indeterminate finding is identified and
- The proportion of ctDNA not detected participants whose indeterminate findings is ultimately confirmed to be benign.
- Sensitivity for local recurrence [ Time Frame: 6 years ]Sensitivity for local recurrence defined as the proportion of participants who have localized recurrence (e.g., in the absence of distant metastasis) who have ctDNA detected at or before the time of clinical detection of a localized recurrence; using landmark and serial timepoints.
- Index Cancer-Specific Survival (ICSS) [ Time Frame: 6 years ]Index Cancer-Specific Survival (ICSS) defined as the time from the date of diagnosis until the date of death from the subject's Index Cancer. Subjects who are still alive at the end of the study observation period will be censored at the time of last known vital status.
- Overall Survival (OS) [ Time Frame: 6 years ]Overall Survival (OS) defined as the time from the date of diagnosis until the date of death from any cause. Subjects who are still alive at the end of the study observation period will be censored at the time of last known vital status.
- Rate of ctDNA clearance with adjuvant chemotherapy [ Time Frame: 6 years ]Rate of ctDNA clearance with adjuvant chemotherapy defined as the proportion of patients who have ctDNA detected at the pre-enrollment timepoint whose ctDNA becomes undetectable at the Landmark timepoint.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Age > 18 years old AND
- Were treated with curative intent AND
- Are planning to undergo regular follow-up and monitoring for cancer recurrence per standard of care at the enrolling site AND
- Provided written informed consent to participate in the study AND
- Are willing to have de-identified clinical data shared with investigators at regular intervals as outlined in the study protocol and informed consent AND
- Are willing to provide blood samples at enrollment and at subsequent clinical visits coinciding with standard of care follow-up, for up to 5 years as outlined in the study protocol and informed consent AND
- Have at least one blood sample collected 4-12 weeks after completion of primary treatment of the Index Cancer
- Have a histologically confirmed Index Cancer that qualifies for inclusion, defined as:
Primary Study Cohorts
- Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III),
- Cohort 2: Non-small cell lung cancer (stage II-III),
- Cohort 3: Invasive breast carcinoma with all of the following:
Clinical stage T1-4/N0-3/M0 at presentation AND Completed preoperative systemic chemotherapy-containing regimen AND Underwent definitive surgical resection of the primary tumor AND Has pathological evidence of residual invasive carcinoma in the breast and/or axillary lymph nodes AND Hormone receptor and HER2 status are known
Exploratory Cohorts
- Cohort 4: Stage IIb-III cutaneous melanoma or limited (resectable) stage IV melanoma treated with curative intent,
- Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III),
- Cohort 6: Gastric adenocarcinoma (stage II-III),
- Cohort 7: Surgically resected pancreatic adenocarcinoma,
- Cohort 8: Invasive squamous cell carcinoma of the head and neck (includes stage I-III oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, paranasal sinus, and salivary gland cancers),
- Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma (defined as stage IC-III or stage I that has high grade (grade 3-4) or clear cell histology),
- Cohort 10: High-risk endometrial carcinoma (defined as having any of the following: serous or clear cell adenocarcinoma histology (any stage), grade 3 or 4 deeply invasive (T1b or greater) endometrioid carcinoma, stage III disease (any histology)),
- Cohort 11: High-risk renal cell carcinoma (defined as high grade (grade 3-4) stage II, stage III or limited (resectable) stage IV treated with curative intent)
Exclusion Criteria:
- History of allogeneic organ or tissue transplant
- Index cancer has neuroendocrine histology
- History of another primary cancer, with the exception of the following (if adequately treated and the patient is without evidence of disease at the time of enrollment): in situ cancers, non-melanoma skin carcinoma, localized low-risk prostate cancer (Gleason score < 6) with PSA in the normal range, and stage I papillary thyroid carcinoma.
- Known distant metastasis at time of enrollment (with the exception of participants with limited/resectable stage IV cutaneous melanoma or RCC)
- Is participating in a clinical trial or another observational study that is evaluating the performance of another genomic test in the post-treatment surveillance setting at predicting/detecting recurrence
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05059444
Contact: Clinical Trial Operations | 8556988887 | mrdoraclestudy@guardanthealth.com |
United States, California | |
Redwood City | Recruiting |
Redwood City, California, United States, 94063 | |
Contact: Clinical Trial Operations |
Study Director: | Study Director | Guardant Health, Inc. |
Responsible Party: | Guardant Health, Inc. |
ClinicalTrials.gov Identifier: | NCT05059444 |
Other Study ID Numbers: |
02-MX-003 |
First Posted: | September 28, 2021 Key Record Dates |
Last Update Posted: | September 9, 2022 |
Last Verified: | September 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma Adenocarcinoma Breast Neoplasms Squamous Cell Carcinoma of Head and Neck Endometrial Neoplasms Carcinoma, Ovarian Epithelial Esophageal Neoplasms Urinary Bladder Neoplasms Neoplasm, Residual Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms by Site Skin Diseases Carcinoma, Squamous Cell |
Urologic Neoplasms Urogenital Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Urologic Diseases Male Urogenital Diseases Breast Diseases Head and Neck Neoplasms Uterine Neoplasms Genital Neoplasms, Female Uterine Diseases Genital Diseases, Female Genital Diseases Ovarian Neoplasms |